Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial

OBJECTIVE: The effectiveness and security of radiofrequency ablation (RFA) in combination with toripalimab (anti‐PD‐1) for the treatment of recurrent hepatocellular carcinoma (HCC) was studied in this article. METHODS: Total of 40 patients were enrolled in the study between September 2019 and Novemb...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Zhenyu, Wang, Junxiao, Tu, Bo, Liu, Yane, Yang, Yuqing, Hou, Li, Yang, Xiang, Liu, Xiaoyan, Xie, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652346/
https://www.ncbi.nlm.nih.gov/pubmed/37814921
http://dx.doi.org/10.1002/cam4.6602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652346/
https://www.ncbi.nlm.nih.gov/pubmed/37814921
http://dx.doi.org/10.1002/cam4.6602

Ejemplares similares